$HCTI
Healthcare Triangle, Inc. Stock $hcti

$hcti Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000160706223000487 Filed on November 13, 2023

Income Statement

Concept	2023 Q4	2023 Q3
Revenue	$7.060M	$7.779M
YoY Change	-37.48%	-34.9%
Cost Of Revenue	$5.530M	$6.072M
YoY Change	-41.65%	-28.75%
Gross Profit	$1.530M	$1.707M
YoY Change	-15.66%	-50.2%
Gross Profit Margin	21.67%	21.94%
Selling, General & Admin	$1.602M	$2.470M
YoY Change	-44.66%	-25.04%
% of Gross Profit	104.71%	144.7%
Research & Development	$104.0K	$54.00K
YoY Change	-96.25%	-96.33%
% of Gross Profit	6.8%	3.16%
Depreciation & Amortization	$4.844M	$710.0K
YoY Change	432.31%	-21.89%
% of Gross Profit	316.6%	41.59%
Operating Expenses	$6.550M	$3.231M
YoY Change	-0.38%	-43.07%
Operating Profit	-$5.020M	-$1.524M
YoY Change	5.44%	-32.18%
Interest Expense	-$305.0K	-$420.0K
YoY Change	267.47%	663.64%
% of Operating Profit
Other Income/Expense, Net	$0.00
YoY Change	-100.0%
Pretax Income	-$5.325M	-$1.939M
YoY Change	9.79%	-15.77%
Income Tax	$7.000K	$4.000K
% Of Pretax Income
Net Earnings	-$5.332M	-$1.943M
YoY Change	9.64%	-16.93%
Net Earnings / Revenue	-75.52%	-24.98%
Basic Earnings Per Share		-$0.45
Diluted Earnings Per Share	-$1.26	-$0.46
COMMON SHARES
Basic Shares Outstanding	4.278M shares	4.278M shares
Diluted Shares Outstanding		4.278M shares

Balance Sheet

Concept	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.234M	$80.00K
YoY Change	-7.98%	-98.07%
Cash & Equivalents	$1.234M	$75.00K
Short-Term Investments
Other Short-Term Assets	$1.259M	$622.0K
YoY Change	54.29%	166.95%
Inventory
Prepaid Expenses
Receivables	$3.236M	$4.000K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$5.729M	$4.893M
YoY Change	-26.07%	-55.84%
LONG-TERM ASSETS
Property, Plant & Equipment	$44.00K	$49.00K
YoY Change	-45.0%	-35.53%
Goodwill		$1.289M
YoY Change		0.0%
Intangibles	$3.611M
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$4.320M	$9.573M
YoY Change	-66.8%	-30.55%
TOTAL ASSETS
Total Short-Term Assets	$5.729M	$4.893M
Total Long-Term Assets	$4.320M	$9.573M
Total Assets	$10.05M	$14.47M
YoY Change	-51.6%	-41.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.953M	$1.161M
YoY Change	31.87%	-20.91%
Accrued Expenses	$0.00
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$3.429M	$3.479M
YoY Change	42.16%	41.83%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.123M	$6.852M
YoY Change	32.12%	35.42%
LONG-TERM LIABILITIES
Long-Term Debt	$888.0K	$0.00
YoY Change
Other Long-Term Liabilities	$500.0K	$1.490M
YoY Change	-77.54%	-33.09%
Total Long-Term Liabilities	$1.388M	$1.490M
YoY Change	-37.66%	-33.09%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.123M	$6.852M
Total Long-Term Liabilities	$1.388M	$1.490M
Total Liabilities	$9.511M	$8.339M
YoY Change	13.56%	14.44%
SHAREHOLDERS EQUITY
Retained Earnings	-$24.91M	-$19.58M
YoY Change	98.16%	163.86%
Common Stock	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$538.0K	$6.127M
YoY Change
Total Liabilities & Shareholders Equity	$10.05M	$14.47M
YoY Change	-51.6%	-41.82%

Cashflow Statement

Concept	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	-$5.332M	-$1.943M
YoY Change	9.64%	-16.93%
Depreciation, Depletion And Amortization	$4.844M	$710.0K
YoY Change	432.31%	-21.89%
Cash From Operating Activities	$1.214M	$0.00
YoY Change	-154.49%	-100.0%
INVESTING ACTIVITIES
Capital Expenditures	$6.000K	$10.00K
YoY Change	-57.14%	-100.78%
Acquisitions
YoY Change
Other Investing Activities	$0.00
YoY Change
Cash From Investing Activities	-$6.000K	-$10.00K
YoY Change	-57.14%	-99.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-49.00K	-50.00K
YoY Change	-91.27%	-100.99%
NET CHANGE
Cash From Operating Activities	1.214M	0.000
Cash From Investing Activities	-6.000K	-10.00K
Cash From Financing Activities	-49.00K	-50.00K
Net Change In Cash	1.159M	-60.00K
YoY Change	-141.35%	-102.16%
FREE CASH FLOW
Cash From Operating Activities	$1.214M	$0.00
Capital Expenditures	$6.000K	$10.00K
Free Cash Flow	$1.208M	-$10.00K
YoY Change	-153.88%	-103.24%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q3	HCTI	Other Income Amount Changes OtherIncomeAmountChanges		usd
CY2023Q3	HCTI	Business Combination Working Capital BusinessCombinationWorkingCapital		usd
CY2023Q3	HCTI	Other Income Loan Forgiveness OtherIncomeLoanForgiveness		usd
CY2023Q3	HCTI	Deferredtaxassetnetofvaluationallowance Deferredtaxassetnetofvaluationallowance		usd
CY2022Q4	HCTI	Deferredtaxassetnetofvaluationallowance Deferredtaxassetnetofvaluationallowance		usd
CY2023Q3	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2023Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
	HCTI	Current Federal Tax Expense Benefits CurrentFederalTaxExpenseBenefits		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
CY2023Q3	us-gaap	Other Noncash Income OtherNoncashIncome		usd
CY2022Q3	us-gaap	Other Noncash Income OtherNoncashIncome		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001839285
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2023Q3	HCTI	Preferential Issue PreferentialIssue		usd
CY2023Q3	HCTI	Adjustment Shares Issued AdjustmentSharesIssued		usd
	HCTI	Adjustment Shares Issued AdjustmentSharesIssued		usd
	HCTI	Income From Ppp IncomeFromPpp		usd
	us-gaap	Short Term Lease Payments ShortTermLeasePayments		usd
	HCTI	Increase Decrease In Intangible Assets IncreaseDecreaseInIntangibleAssets		usd
	HCTI	Current Federal Tax Expense Benefits CurrentFederalTaxExpenseBenefits		usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40903
	dei	Entity Registrant Name EntityRegistrantName	HEALTHCARE TRIANGLE, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-3559776
	dei	Entity Address Address Line1 EntityAddressAddressLine1	7901 Stoneridge Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 220
	dei	Entity Address City Or Town EntityAddressCityOrTown	Pleasanton
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94588
	dei	City Area Code CityAreaCode	(925)
	dei	Local Phone Number LocalPhoneNumber	270-4812
	dei	Security12b Title Security12bTitle	Common Stock, $0.00001 par value
	dei	Trading Symbol TradingSymbol	HCTI
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4277572	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	75000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1341000	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5592000	usd
CY2023Q3	us-gaap	Other Assets Current OtherAssetsCurrent	622000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	816000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	4893000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	7749000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	49000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	80000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8220000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10570000	usd
CY2023Q3	us-gaap	Goodwill Goodwill	1289000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	1289000	usd
CY2023Q3	HCTI	Dues From Affiliates DuesFromAffiliates	15000	usd
CY2022Q4	HCTI	Dues From Affiliates DuesFromAffiliates	1075000	usd
CY2023Q3	us-gaap	Assets Assets	14466000	usd
CY2022Q4	us-gaap	Assets Assets	20763000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1161000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1481000	usd
CY2023Q3	HCTI	Warrant Liability WarrantLiability	795000	usd
CY2022Q4	HCTI	Warrant Liability WarrantLiability	55000	usd
CY2023Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	3479000	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	2412000	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1417000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2200000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6852000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6148000	usd
CY2023Q3	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	1487000	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	2227000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	8339000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8375000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	HCTI	Preferred Stock Voting Shares PreferredStockVotingShares	6000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4277572	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4170953	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	25703000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	24956000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19576000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12568000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	6127000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	12388000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14466000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20763000	usd
CY2023Q3	us-gaap	Revenues Revenues	7779000	usd
CY2022Q3	us-gaap	Revenues Revenues	11950000	usd
	us-gaap	Revenues Revenues	26143000	usd
	us-gaap	Revenues Revenues	34594000	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	6072000	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	8522000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	20896000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	25113000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	54000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1471000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	695000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3183000	usd
CY2023Q3	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	1101000	usd
CY2022Q3	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	1815000	usd
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	3888000	usd
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	5206000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1364000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1480000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4604000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4282000	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	712000	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	909000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2388000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2464000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	3231000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	5675000	usd
	us-gaap	Operating Expenses OperatingExpenses	11575000	usd
	us-gaap	Operating Expenses OperatingExpenses	15135000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1524000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2247000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6328000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5464000	usd
	us-gaap	Other Income OtherIncome	12000	usd
	us-gaap	Other Income OtherIncome	1087000	usd
CY2023Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-415000	usd
CY2022Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-55000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-663000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-129000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1939000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2302000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6979000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4696000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	37000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	28000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	51000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1943000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2339000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7007000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4747000	usd
CY2023Q3	HCTI	Net Income Per Common Sharebasic And Diluted NetIncomePerCommonSharebasicAndDiluted	-0.46
CY2022Q3	HCTI	Net Income Per Common Sharebasic And Diluted NetIncomePerCommonSharebasicAndDiluted	-0.64
	HCTI	Net Income Per Common Sharebasic And Diluted NetIncomePerCommonSharebasicAndDiluted	-1.66
	HCTI	Net Income Per Common Sharebasic And Diluted NetIncomePerCommonSharebasicAndDiluted	-1.31
CY2023Q3	HCTI	Weighted Average Common Shares Outstanding Basic And Diluted WeightedAverageCommonSharesOutstandingBasicAndDiluted	4228340	shares
CY2022Q3	HCTI	Weighted Average Common Shares Outstanding Basic And Diluted WeightedAverageCommonSharesOutstandingBasicAndDiluted	3602289	shares
	HCTI	Weighted Average Common Shares Outstanding Basic And Diluted WeightedAverageCommonSharesOutstandingBasicAndDiluted	4228340	shares
	HCTI	Weighted Average Common Shares Outstanding Basic And Diluted WeightedAverageCommonSharesOutstandingBasicAndDiluted	3602289	shares
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	8051000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-1943000	usd
CY2023Q3	HCTI	Issue Of Options Isonso IssueOfOptionsIsonso	20000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	0	usd
CY2023Q3	HCTI	Adjustment Shares Issued Shares AdjustmentSharesIssuedShares	-291000	shares
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	6127000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	12388000	usd
	HCTI	Issue Of Options Isonso IssueOfOptionsIsonso	197000	usd
	HCTI	Preferential Issue PreferentialIssue	499000	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	51000	usd
	us-gaap	Profit Loss ProfitLoss	-7007000	usd
	HCTI	Adjustment Shares Issued Shares AdjustmentSharesIssuedShares	-291000	shares
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	6127000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	14106000	usd
CY2022Q3	HCTI	Stock Compensation Expenses StockCompensationExpenses	13000	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-2339000	usd
CY2022Q3	HCTI	Common Stock Issued In Connection With Private Placement CommonStockIssuedInConnectionWithPrivatePlacement	393000000	shares
CY2022Q3	HCTI	Issuance Of Common Stock In Connection With Private Placement IssuanceOfCommonStockInConnectionWithPrivatePlacement	3580000	usd
CY2022Q3	HCTI	Issuance Of Warrants In Connection With Private Placement IssuanceOfWarrantsInConnectionWithPrivatePlacement	2308000	usd
CY2022Q3	HCTI	Common Stock Repurchased CommonStockRepurchased	-91000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	17577000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	16135000	usd
	HCTI	Stock Compensation Expenses StockCompensationExpenses	32000	usd
	HCTI	Cash Collected On Common Stock Options Shares CashCollectedOnCommonStockOptionsShares	2614000	shares
	HCTI	Cash Collected On Common Stock Options CashCollectedOnCommonStockOptions	10000	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	350000	usd
	us-gaap	Profit Loss ProfitLoss	-4747000	usd
	HCTI	Common Stock Issued In Connection With Private Placement CommonStockIssuedInConnectionWithPrivatePlacement	393000000	shares
	HCTI	Issuance Of Common Stock In Connection With Private Placement IssuanceOfCommonStockInConnectionWithPrivatePlacement	3580000	usd
	HCTI	Common Stock Repurchased CommonStockRepurchased	-91000	usd
	HCTI	Issuance Of Warrants In Connection With Private Placement IssuanceOfWarrantsInConnectionWithPrivatePlacement	2308000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	17577000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7007000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4747000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2388000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2464000	usd
	HCTI	Common Stock Issued For Services CommonStockIssuedForServices	51000	usd
	HCTI	Common Stock Issued For Services CommonStockIssuedForServices	350000	usd
	HCTI	Income From Ppp IncomeFromPpp	-1069000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	194000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	40000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1396000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2970000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-195000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-129000	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-1060000	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	134000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-320000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-405000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-783000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	176000	usd
	us-gaap	Short Term Lease Payments ShortTermLeasePayments	146000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2826000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-372000	usd
	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	7000	usd
	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	26000	usd
	HCTI	Increase Decrease In Intangible Assets IncreaseDecreaseInIntangibleAssets	-3279000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3305000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	10000	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	1067000	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	244000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	91000	usd
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	500000	usd
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	5888000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1567000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6051000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1266000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	2374000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1341000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1770000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	75000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4144000	usd
	us-gaap	Interest Expense InterestExpense	663000	usd
	us-gaap	Interest Expense InterestExpense	129000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	28000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	51000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84F_eus-gaap--UseOfEstimates_zHCVY6ZGDtau" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><span id="xdx_86C_z2SbX1q9uNWP" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements is in conformity with GAAP which requires us to make estimates, judgments and assumptions that affect the financial statements and the notes thereto. These estimates are based on information available as of the date of the financial statements. On a regular basis, management evaluates these estimates and assumptions. Items subject to such estimates and assumptions include, but are not limited to:</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 20px; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">•</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 7px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the standalone selling price for each distinct performance obligation</span></td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 20px; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">•</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 7px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the determination of the period of benefit for amortization of deferred costs.</span></td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 20px; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">•</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 7px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the fair value of assets acquired, and liabilities assumed for business combinations.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">•</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share based compensation including warrants</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>
	HCTI	Total Segment Operating Profit Percentage Changes TotalSegmentOperatingProfitPercentageChanges	-1.45	pure
	HCTI	Unallocated Costs UnallocatedCosts	5652000	usd
	HCTI	Unallocated Costs UnallocatedCosts	7147000	usd
	HCTI	Less Unallocated Costs Amount Changes LessUnallocatedCostsAmountChanges	-1495000	usd
	HCTI	Less Unallocated Costs Percentage Changes LessUnallocatedCostsPercentageChanges	-0.21	pure
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-6328000	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-5654000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	7779000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	11950000	usd
CY2023Q3	HCTI	Changes Amount ChangesAmount	-4171000	usd
CY2023Q3	HCTI	Changes Percentage ChangesPercentage	-0.35	pure
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	26143000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	34594000	usd
	HCTI	Changes Amount ChangesAmount	-8451000	usd
	HCTI	Changes Percentage ChangesPercentage	-0.24	pure
CY2023Q3	HCTI	Total Segment Operating Profit TotalSegmentOperatingProfit	108000	usd
CY2022Q3	HCTI	Total Segment Operating Profit TotalSegmentOperatingProfit	260000	usd
CY2023Q3	HCTI	Total Segment Operating Profit Amount Changes TotalSegmentOperatingProfitAmountChanges	-152000	usd
CY2023Q3	HCTI	Total Segment Operating Profit Percentage Changes TotalSegmentOperatingProfitPercentageChanges	-0.58	pure
CY2023Q3	HCTI	Unallocated Costs UnallocatedCosts	1632000	usd
CY2022Q3	HCTI	Unallocated Costs UnallocatedCosts	2507000	usd
CY2023Q3	HCTI	Less Unallocated Costs Amount Changes LessUnallocatedCostsAmountChanges	-875000	usd
CY2023Q3	HCTI	Less Unallocated Costs Percentage Changes LessUnallocatedCostsPercentageChanges	-0.35	pure
CY2023Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1524000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2247000	usd
CY2023Q3	HCTI	Income From Operations Amount Changes IncomeFromOperationsAmountChanges	723000	usd
CY2023Q3	HCTI	Income From Operations Percentage Changes IncomeFromOperationsPercentageChanges	0.32	pure
CY2023Q3	HCTI	Other Income Percentage Changes OtherIncomePercentageChanges	0	pure
CY2023Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	415000	usd
CY2022Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	55000	usd
CY2023Q3	HCTI	Interest Expense Amount Changes InterestExpenseAmountChanges	-360000	usd
CY2023Q3	HCTI	Interest Expense Percentage Changes InterestExpensePercentageChanges	-6.55	pure
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1939000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2302000	usd
CY2023Q3	HCTI	Net Income Loss Before Income Tax Expenses Amount Changes NetIncomeLossBeforeIncomeTaxExpensesAmountChanges	363000	usd
CY2023Q3	HCTI	Net Income Loss Before Income Tax Expenses Percentage Changes NetIncomeLossBeforeIncomeTaxExpensesPercentageChanges	0.16	pure
	HCTI	Total Segment Operating Profit TotalSegmentOperatingProfit	-676000	usd
	HCTI	Total Segment Operating Profit TotalSegmentOperatingProfit	1493000	usd
	HCTI	Total Segment Operating Profit Amount Changes TotalSegmentOperatingProfitAmountChanges	-2169000	usd
	HCTI	Income From Operations Amount Changes IncomeFromOperationsAmountChanges	-674000	usd
	HCTI	Income From Operations Percentage Changes IncomeFromOperationsPercentageChanges	-0.12	pure
	us-gaap	Other Noncash Income OtherNoncashIncome	12000	usd
	us-gaap	Other Noncash Income OtherNoncashIncome	1087000	usd
	HCTI	Other Income Amount Changes OtherIncomeAmountChanges	-1075000	usd
	HCTI	Other Income Percentage Changes OtherIncomePercentageChanges	-0.99	pure
	us-gaap	Interest Expense Debt InterestExpenseDebt	663000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	129000	usd
	HCTI	Interest Expense Amount Changes InterestExpenseAmountChanges	-534000	usd
	HCTI	Interest Expense Percentage Changes InterestExpensePercentageChanges	-4.14	pure
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-6979000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-4696000	usd
	HCTI	Net Income Loss Before Income Tax Expenses Amount Changes NetIncomeLossBeforeIncomeTaxExpensesAmountChanges	-2283000	usd
	HCTI	Net Income Loss Before Income Tax Expenses Percentage Changes NetIncomeLossBeforeIncomeTaxExpensesPercentageChanges	-0.49	pure
CY2023Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	16473000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8253000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8220000	usd
CY2023Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	4196000	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	5592000	usd
CY2022	HCTI	Allowance For Uncollectible Accounts AllowanceForUncollectibleAccounts	222000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	16473000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5903000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10570000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	701000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	857000	usd
CY2023Q3	HCTI	Warrant Liabilities WarrantLiabilities	795000	usd
CY2023Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	1487000	usd
CY2023Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	816000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	126000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	119000	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	77000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	39000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	49000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	80000	usd
	us-gaap	Depreciation Depreciation	10000	usd
	us-gaap	Depreciation Depreciation	8000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths	636000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Two FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo	2547000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Three FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree	2547000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Four FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour	2489000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8220000	usd
CY2023Q3	HCTI	Due From Other Related Party Noncurrent DueFromOtherRelatedPartyNoncurrent	946000	usd
CY2022Q3	HCTI	Due From Other Related Party Noncurrent DueFromOtherRelatedPartyNoncurrent	334000	usd
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	67000	usd
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	49000	usd
CY2023Q3	HCTI	Due From Related Party DueFromRelatedParty	9000	usd
CY2022Q3	HCTI	Due From Related Party DueFromRelatedParty	0	usd
	us-gaap	Proceeds From Sale Of Other Assets1 ProceedsFromSaleOfOtherAssets1	4500000	usd
	HCTI	Weighted Average Price Of Stock Amount WeightedAveragePriceOfStockAmount	700000	usd
	HCTI	Unvested Common Stock UnvestedCommonStock	8372	shares
	HCTI	Earnout Payment EarnoutPayment	2500000	usd
CY2023Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2209000	usd
	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2022-04-30
CY2023Q3	us-gaap	Goodwill Gross GoodwillGross	1289000	usd
CY2023Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Indefinite Lived Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets	6018000	usd
CY2023Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	1289000	usd
CY2023Q3	us-gaap	Cash Cash	970000	usd
CY2023Q3	HCTI	Business Combination Acquisition Accounts Receivables BusinessCombinationAcquisitionAccountsReceivables	3142000	usd
CY2023Q3	HCTI	Business Combination Acquisition Other Assets Current BusinessCombinationAcquisitionOtherAssetsCurrent	11419000	usd
CY2023Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	758000	usd
CY2023Q3	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	2209000	usd
CY2023Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther	679000	usd
CY2023Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities	3646000	usd
CY2023Q3	HCTI	Net Working Capital Acquired NetWorkingCapitalAcquired	7773000	usd
CY2023Q3	HCTI	Total Business Acquisitions Purchase Price TotalBusinessAcquisitionsPurchasePrice	7773000	usd
CY2023Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	10.66
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P4Y
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	2386000	usd
CY2023Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P4Y
CY2023Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	2386000	usd
CY2023Q1	HCTI	Unvested Warrant Weighted Average Grant Date UnvestedWarrantWeightedAverageGrantDate	5.22
CY2023Q1	HCTI	Vested Warrant Weighted Average Grant Date VestedWarrantWeightedAverageGrantDate	5.64
CY2023Q1	HCTI	Unvested Warrant Weighted Average Grant Date UnvestedWarrantWeightedAverageGrantDate	5.22
CY2023Q2	HCTI	Vested Warrant Weighted Average Grant Date VestedWarrantWeightedAverageGrantDate	5.64
CY2023Q2	HCTI	Unvested Warrant Weighted Average Grant Date UnvestedWarrantWeightedAverageGrantDate	5.22
CY2023Q3	HCTI	Vested Warrant Weighted Average Grant Date VestedWarrantWeightedAverageGrantDate	5.64
CY2023Q3	HCTI	Unvested Warrant Weighted Average Grant Date UnvestedWarrantWeightedAverageGrantDate	5.22
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	795000	usd
	HCTI	Estimated Fair Value Of Common Stock Warrant EstimatedFairValueOfCommonStockWarrant	5.22
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	10.66
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Short Term Debt Interest Rate Increase ShortTermDebtInterestRateIncrease	0.01	pure
CY2023Q3	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	2997000	usd
CY2022Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	3212000	usd
CY2023Q3	us-gaap	Line Of Credit Facility Fair Value Of Amount Outstanding LineOfCreditFacilityFairValueOfAmountOutstanding	482	usd
CY2023Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1884000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2578000	usd
CY2023Q3	HCTI	Stockbased Compensation StockbasedCompensation	-58000	usd
CY2022Q4	HCTI	Stockbased Compensation StockbasedCompensation	-27000	usd
CY2022Q4	HCTI	Other Income Loan Forgiveness OtherIncomeLoanForgiveness	292000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1826000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2843000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1826000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2843000	usd
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	4000	usd
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	37000	usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	4000	usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	37000	usd
	HCTI	Total Income Expenses Benefit TotalIncomeExpensesBenefit	4000	usd
	HCTI	Total Income Expenses Benefit TotalIncomeExpensesBenefit	37000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	208514	shares
CY2023Q1	HCTI	Additions To Plan AdditionsToPlan	200000	shares
CY2023Q1	HCTI	Nonqualified Stock Options Nso NonqualifiedStockOptionsNso	88076	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	12386	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	332824	shares
CY2023Q2	HCTI	Nonqualified Stock Options Nso NonqualifiedStockOptionsNso	11226	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	70000000	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	274050	shares
CY2023Q3	HCTI	Nonqualified Stock Options Nso NonqualifiedStockOptionsNso	4786	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	25000000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	375006	shares
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	546000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1943000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2339000	usd
CY2023Q3	HCTI	Weighted Average Shares Outstanding Used In Basic Per Common Share Computations WeightedAverageSharesOutstandingUsedInBasicPerCommonShareComputations	4228340	shares
CY2022Q3	HCTI	Weighted Average Shares Outstanding Used In Basic Per Common Share Computations WeightedAverageSharesOutstandingUsedInBasicPerCommonShareComputations	3602289	shares
CY2023Q3	HCTI	Weighted Average Basic Diluted Eps WeightedAverageBasicDilutedEps	-0.46	shares
CY2022Q3	HCTI	Weighted Average Basic Diluted Eps WeightedAverageBasicDilutedEps	-0.64	shares

Files In Submission

Name	View Source	Status
hcti-20230930_cal.xml	Edgar Link	unprocessable
hcti-20230930_lab.xml	Edgar Link	unprocessable
hcti-20230930_pre.xml	Edgar Link	unprocessable
hcti-20230930_def.xml	Edgar Link	unprocessable
0001607062-23-000487-index-headers.html	Edgar Link	pending
0001607062-23-000487-index.html	Edgar Link	pending
0001607062-23-000487.txt	Edgar Link	pending
0001607062-23-000487-xbrl.zip	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex31_2.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
ex32_2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
hcti-20230930.xsd	Edgar Link	pending
hcti093023form10q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
hcti093023form10q_htm.xml	Edgar Link	completed
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HCTI
Healthcare Triangle, Inc. Stock $hcti

2023 Q4 Form 10-Q Financial Statement

#000160706223000487 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCTI Healthcare Triangle, Inc. Stock $hcti

2023 Q4 Form 10-Q Financial Statement

#000160706223000487 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCTI
Healthcare Triangle, Inc. Stock $hcti